Reuters logo
BRIEF-Spark Therapeutics and Pfizer amend license agreement for investigational SPK-9001 in hemophilia B
November 7, 2017 / 12:48 PM / a month ago

BRIEF-Spark Therapeutics and Pfizer amend license agreement for investigational SPK-9001 in hemophilia B

Nov 7 (Reuters) - Spark Therapeutics Inc

* Spark Therapeutics and Pfizer amend license agreement for investigational SPK-9001 in hemophilia B

* Spark Therapeutics Inc - Co transferring enhanced SPK-9001 manufacturing process to Pfizer

* Spark Therapeutics - Co, Pfizer ‍have entered into amendment to their license agreement for SPK-9001

* Spark Therapeutics - ‍Subject to terms of amendment, Spark Therapeutics will receive from pfizer an initial $10 million cash payment​

* Spark Therapeutics Inc - Will enroll up to five additional participants in current phase 1/2 clinical trial​

* Spark - ‍Subject to amendment, to receive from Pfizer up to additional $15 million in potential milestone payments upon completion of transition activities​

* Spark Therapeutics - ‍Activities outlined in amended agreement will occur parallel to Pfizer’s ongoing preparation to assume responsibility for SPK-9001 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below